Compare ATOM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | ADCT |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 136.1M |
| IPO Year | 2016 | 2019 |
| Metric | ATOM | ADCT |
|---|---|---|
| Price | $3.99 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 422.3K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.41 | ★ 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | $62,000.00 | ★ $81,357,000.00 |
| Revenue This Year | $527.69 | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $1.89 | $0.78 |
| 52 Week High | $12.37 | $4.98 |
| Indicator | ATOM | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.06 |
| Support Level | N/A | $1.03 |
| Resistance Level | N/A | $1.45 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 68.94 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).